Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

Clinical trial NCT07407465 · RECRUITING

Trial details

NCT number: NCT07407465
Sponsor: Gruppo Oncologico del Nord-Ovest
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Colorectal Cancer Colorectal Adenocarcinoma Rectal Adenocarcinoma Rectal Cancer, Adenocarcinoma Rectal Cancer, Metastatic Colon Cancer Metastatic Colon Cancer Adenocarcinoma

Start date: 2025-10-20
Primary completion: 2027-10-20
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.